Population-based survival after mantle cell lymphoma in Norway and Denmark: Limited impact of earlier BTKi access [0.03%]
Mikkel Runason Simonsen,Marianne B Jerm,Tom B Johannesen et al.
Mikkel Runason Simonsen et al.
Response to 'Statistical considerations in the comparison of immunotherapy and chemotherapy for POD24 follicular lymphoma' [0.03%]
Ángel Serna,Víctor Navarro,Pau Abrisqueta
Ángel Serna
Authors' reply to 'Comments on dose-dependent impairment of brain functional and microstructural connectivity during leukaemia chemotherapy' [0.03%]
Ashleigh P Scott,Ada Lo,Ying Xia et al.
Ashleigh P Scott et al.
Dynamic improvement of the treatment-free remission prognostic score by prolonging MR4 duration in chronic myeloid leukaemia [0.03%]
Mai Fujita,Hiroshi Ureshino
Mai Fujita
Preliminary investigation into the association of serum free kappa light chains with risk stratification, clonal evolution and precision therapy in multiple myeloma [0.03%]
Chenbo Yang,Jingbo Xiao,Na Zhao et al.
Chenbo Yang et al.
Multiple myeloma (MM) is a highly heterogeneous plasma cell malignancy whose progression and relapse are influenced by clonal heterogeneity. Although serum free light chains (sFLCs) are key biomarkers for tumour burden assessment, the clini...
Clinical features and prognostic factors of adult systemic chronic active EBV disease: A retrospective analysis in Japan [0.03%]
Aika Fuseya,Masahide Yamamoto,Miwako Nishio et al.
Aika Fuseya et al.
Systemic chronic active Epstein-Barr virus disease (sCAEBV) is a life-threatening disorder characterized by Epstein-Barr virus (EBV) infection in T cells and/or natural killer (NK) cells leading to systemic inflammation. We retrospectively ...
Tyler Gallo,C William Heise,Steven C Curry et al.
Tyler Gallo et al.
Clinical decision support (CDS) can potentially improve the rate of heparin-induced thrombocytopenia (HIT) diagnostic testing for patients who are at increased risk. We implemented and evaluated CDS utilizing the HIT computerized risk (HIT-...
Non-infectious fever defines a subgroup of patients with poorer survival outcomes in high-risk myelodysplastic syndrome [0.03%]
Takahisa Nakamura,Haruya Okamoto,Chika Maekura et al.
Takahisa Nakamura et al.
Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotype [0.03%]
Matthew J Rees,Binoy Yohannan,Susan Geyer et al.
Matthew J Rees et al.
Renal response (RenR) in light-chain (AL) amyloidosis is associated with a lower risk of end-stage kidney disease and improved survival. However, substantial variation exists in the time to and depth of RenR. We investigated variables assoc...
Thromboembolic risk in superficial vein thrombosis involving the saphenopopliteal versus saphenofemoral junction [0.03%]
Crhistian-Mario Oblitas,Marina López-Rubio,Rubén Alonso-Beato et al.
Crhistian-Mario Oblitas et al.